Research programme: osteoporosis therapeutics - Acologix
Alternative Names: AC-130 series; OSM; Ossomar; Osteoporosis therapeutics research programme - Acologix IncLatest Information Update: 16 Jul 2016
At a glance
- Originator Acologix
- Class Peptides; Small molecules
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis(Prevention) in USA (PO)
- 11 May 2005 A lead compound, ossomar is available for licensing in (http://www.acologix.com)